Utilization of negative checkpoint regulators (NCRs) for cancer immunotherapy has garnered significant interest with the completion of clinical trials demonstrating efficacy. While the results of monotherapy treatments are compelling, there is increasing emphasis on combination treatments in an effort to increase response rates to treatment. One of the most recently discovered NCRs is VISTA (V-domain Igcontaining Suppressor of T cell Activation). In this review, we describe the functions of this molecule in the context of cancer immunotherapy. We also discuss factors that may influence the use of anti-VISTA antibody in combination therapy and how genomic analysis may assist in providing indications for treatment.
| INTRODUCTION
The approval of antibodies targeting cytotoxic T lymphocyte antigen 4 (CTLA-4) and the programmed death receptor 1 (PD-1)-programmed death ligand 1 (PD-L1) pathway revitalized interest in utilizing antibodies against negative checkpoint regulators to counter the normally suppressive effects of these molecules.
VISTA
1 (also known as PD-1H, 2 DD1α, 3 c10orf54, Gi24, 4 Dies1, 5 and SISP1 6 ) , is one such NCR that is currently in phase I clinical trials (NCT02671955). Here, we summarize the literature and the potential use of antagonist anti-VISTA antibodies in immuno-oncology and agonists for the management of inflammation. In addition, we discuss how antibodies targeting NCRs may be used in combination with other agents and how genomic analysis can assist in providing indications for usage.
| VISTA STRUCTURE AND EXPRESSION
VISTA is a type I transmembrane protein consisting of a single tightly conserved functional role. 1,2 By comparison, the human and mouse PD-1 tails only share 59% identity.
In contrast with results using the whole protein, analysis of the IgV domain of VISTA shows that this has the greatest homology with PD-L1. Subsequent sequence prediction and modeling after PD-L1 shows that the IgV domain of VISTA possesses the canonical disulfide bond between the putative B and F strands. However, it also uniquely has four additional invariant cysteines (three predicted to be within the IgV domain and an additional one in the stalk region). 1 Indeed, the VISTA IgV domain is the most divergent among both B7 member and
IgV domains in general. 7 While it is possible that the conserved cysteine residues contribute to dimerization, efforts to identify multimeric complexes have been unsuccessful (data not shown).
Within the conserved cytoplasmic tail, VISTA resembles CD28 and CTLA-4. While it does not possess a classic ITIM/ITAM motif, setting it aside from other B7 co-receptor molecules, VISTA has a conserved Src homology 2 (SH2)-binding (YxxQ, potentially capable of binding STAT proteins) motif in the middle of the cytoplasmic tail and three C-terminal SH3-binding domains (PxxP, two in CD28 and one in . It remains to be tested whether the motifs within the VISTA tail actually recruit SH2/SH3 domain adapter proteins as was demonstrated for CD28 and CTLA-4. Taken together, these data suggest that VISTA may act as both a ligand and receptor in regulating immune responses. [1] [2] [3] [8] [9] [10] [11] [12] Emerging studies from a number of labs support this concept.
In mice, VISTA mRNA is expressed in embryonic stem cells at the blastocyte stage of development. Studies suggest it regulates signaling of bone morphogenetic protein 4, which subsequently impact in vitro stem cell differentiation. 5, 13, 14 In adult mice at steady state, mRNA for VISTA is primarily confined to hematopoietic tissues including bone marrow, thymus, spleen, and lymph node. The lung and small intestine also have high levels of expression, which is probably due to the presence of leukocyte infiltrate in these tissues. Low but detectable mRNA levels of VISTA are also observed in the heart, brain, muscle, kidney, testis, and placenta. 1,2 However, extensive immunohistological analysis in mice support the conclusion that VISTA protein is exclusively expressed within the hematopoietic compartment (data not shown).
Within the hematopoietic compartment, overall the highest levels 12 Histology of 12-month old mice showed increased immune cell infiltration in the liver, lung, and pancreas in comparison to controls but lacked overt autoimmunity. However, when VISTA deficient mice were crossed to transgenic mice expressing a TCR that recognizes myelin oligodendrocyte protein (2D2), they had a high incidence of spontaneous autoimmune encephalomyelitis.
12
Lee and co-workers also created VISTA deficient mice using a different approach. They floxed exons 2 and 3 with loxP sites and intercrossed them with EIIa-cre mice, which can lead to germline deletion of VISTA. Subsequent VISTA heterozygous mice were backcrossed onto a C57BL/6 background and then intercrossed with each other to obtain VISTA deficient mice. In contrast to the Lexicon VISTA deficient mouse, these mice do develop overt autoimmunity with age, manifesting as increased skin inflammation, anti-nuclear antibody titers, and immune complex deposition in the kidneys. 3 The basis for this difference is currently unknown; however, one possibility is that the Lee mice may contain residual 129 genes as they were only backcrossed seven generations. 3 Another is that the normal flora in these mice may be different and subsequently influencing the immune microenvironment to be more inflammatory.
| VISTA FUNCTIONS AS BOTH A LIGAND AND A RECEPTOR
The notion that VISTA functions as a ligand initially developed from mediators within the TME and heavily dependent on IFNγ or TLRmediated signaling pathways. [28] [29] [30] [31] VISTA is a member of the B7 family of NCR and represents a new target for immunotherapy. Unlike PD-L1, which is detected in both tumor and hematopoietic lineages, VISTA expression is constitutive in vivo and is primarily, if not exclusively, expressed within the hematopoietic lineage. 1, 32 In multiple mouse models, VISTA expression is upregulated in the TME and plays a critical role in shaping anti-tumor immunity. 32 In particular, VISTA expression is higher on tumor infiltrat- These promising results of tumor studies in mice led to a phase I anti-VISTA monotherapy clinical trial (NCT02671955) which is currently ongoing. However, the fact that VISTA and PD-1 appear to regulate non-redundant pathways of immune suppression in the TME offers significant excitement for combination therapy.
| TARGETING VISTA IN THE CONTEXT OF CONTEMPORARY ANTIBODY COMBINATION THERAPY IN IMMUNO-ONCOLOGY
It is now becoming apparent that multiple pathways exist to maintain the immunosuppressed nature of the TME. In order to reach higher response rates, treatment strategies must impact multiple suppressive arms concurrently (depicted in Figure 2 ). 
| PD-1-PD-L1
The PD-1 pathway followed ipilimumab into the clinic with FDA approval for anti-PD-1 antibodies nivolumab (Opdivo; BristolMyers Squibb, New York, NY, USA) and pembrolizumab (Keytruda;
Merck, Kenilworth, NJ, USA) in 2015 and 2016 respectively. PD-1 is a NCR, but in contrast with CTLA-4, PD-1 blocks PI3K activation while CTLA-4 binds to phosphatase PP2A leading to inhibition of Akt phosphorylation. 46 The expression of the ligands PD-L1 and PD-L2 is broader and can be induced on many cell types, including tumor cells, after exposure to IFNγ. 47 The effects of PD-1 blockade appear to be localized to the periphery at the tumor site itself and involve releasing exhausted T cells to allow restoration of effector function.
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Initial phase I trials reported that PD-L1 may serve as a predictive biomarker for targeting the PD-1 pathway. 49 However, it is now becoming clear that some patients will respond even if their tumors are characterized as PD-L1 negative or low. 50 Furthermore, the observed increased response rate does not translate to a survival benefit. 51 In metastatic melanoma patients undergoing anti-PD-1 therapy with pembrolizumab, it was found that while PD-L1 expression correlates with outcomes, a better predictor of response is a high density of CD8
T cells in the margin of the tumor.
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Although there is ample evidence supporting a role for VISTA in suppressing the activities of resting T cells, its role in suppressing effector cell function within the TME is yet to be resolved. Synergistic effects of anti-VISTA and anti-PD-L1 occurred in CT26 colon cancer in mice which led to reduced tumor growth and increased long-term survival in comparison to monotherapy treatment of each. This also correlated with increased production of IFNγ, TNFα, and granzyme B by CD8 T cell from tumor draining lymph nodes after in vitro restimulation. 34 In a murine model of squamous cell carcinoma using a different anti-VISTA antibody clone, no benefit on tumor growth was observed in combining anti-VISTA and anti-PD-1 treatment.
However, there was a striking increase in CD8 T cell effector function when anti-VISTA was used alone or in combination with anti-PD-1 in comparison to controls. 33 Results with both of these studies suggest that the effects of targeting VISTA and the PD-1-PD-L1 axis are non-redundant. However, the extent to which the effects of targeting VISTA are due to effects on CD8 T cells, Tregs, and tumor infiltrating myeloid cells is yet to be determined. 
| PD-1 and CTLA-4 in combination

CTLA-4
hi was strongly correlated with responsiveness. 54 As CTLA-4 blockade appears to increase the frequency of responding antigen-specific T cells, 36, 55 and this is a predictive biomarker for PD-1 therapy, the mechanisms of these two treatments is highly complementary.
Response rates for CTLA-4 and PD-1 from clinical trial are promising. A phase II trial of patients with advanced melanoma showed an overall response rate (ORR) of 61% with the combination of nivolumab and ipilimumab as compared to 11% for ipilimumab alone. 56 Based on these results, the combination was granted accelerated FDA approval for patients with BRAF V600 wildtype unresectable or metastatic melanoma. Subsequently, a phase III study tested either nivolumab alone, nivolumab plus ipilimumab, or ipilimumab alone in a 1:1:1 ratio of 945 untreated advanced melanoma patients. 57 Nivolumab alone or the combination of nivolumab and ipilimumab resulted in significantly longer progression-free survival and higher ORR than did treatment with ipilimumab alone. In patients with PD-L1 negative tumors, the combination was better than either treatment alone. In PD-L1 positive tumors, both the nivolumab alone and combination groups were effective in increasing survival, although there was some difference in ORR. 57 As discussed above, PD-L1 expression may be an indication of the presence of a responding T cell pool, which may be effec- greatly expanded in many mouse models 60, 61 and in human cancers such as colon, breast, melanoma, and pancreatic, among others.
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They inhibit T cell activity through multiple different mechanisms ultimately leading to increased tumor burden 59 including nutrient depletion, 64,65 disrupting TCR signal transduction, 66 abrogating T cell migration, 67, 68 and utilizing the PD-L1-PD-1 pathway as a mechanism to suppress T cells. 
| Combination therapies with agonist antibodies
In addition to antibody blockade of negative checkpoints, some treatment strategies employ agonist antibodies that target costimulatory molecules to convey activating signals to T cells. These agents appear to work best when combined with blockade of negative checkpoints-"removing the brakes". Additional work has focused on effects of TNFR superfamily members. One study tested an allogeneic cell-based vaccine that secreted Fc-OX40L, Fc-ICOSL, or Fc-4-1BBL versus systemic agonist antibody and found that OX40 was the most effectively targeted pathway. 89 In murine tumor models, OX40 agonist antibody has enhanced survival as a monotherapy 90 or combined with CTLA-4 blockade. Anti-CD137 (4-1BB) antibody has been effective in monotherapy in preclinical models including melanoma, breast, and colon carcinomas. 92 However, early phase I trials using this antibody were terminated because of cases of severe hepatotoxicity. 93 Newer trials are currently underway using lower doses of anti-CD137 antibodies to treat patients with melanoma, renal cell carcinoma, and ovarian cancer.
| Perspectives on combination therapy with anti-VISTA
As depicted in Figure 2 , there are multiple mechanisms that immunotherapies can target. In theory, the best results would occur when mechanisms are non-overlapping. As discussed, effects of an antagonist anti-VISTA antibody appear to be non-overlapping with CTLA-4
and PD-1-PD-L1 pathways. 
| GENOMIC APPROACHES TO IMMUNOTHERAPY RESPONSE
The widespread availability of patient genomic data has made computational approaches to studying tumor immunology increasingly accessible. Multi-dimensional datasets such as the Cancer Genome Atlas (TCGA) integrate expression, sequencing, and methylation data from large numbers of patients with multiple tumor types. These datasets enable simple pan-cancer comparisons to be made, such as the landscape of VISTA expression across multiple tumor types ( Figure 3A ).
In addition to these superficial comparisons, several methods have been developed that use these data to more deeply characterize the and was utilized to identify cellular proportions that were predictive of patient survival in an assembly of 166 independent datasets encompassing 39 different cancer types.
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In addition to expression-based methods, several studies have also shown the capability of using DNA methylation data to infer immune infiltration from patient Illumina Infinium 25k or 450k methylation arrays. [105] [106] [107] These methods are dependent on identifying the differentially methylated CpGs that are unique to distinct immune cell subsets.
While promising, these approaches are not as developed as expressionbased methods due to the lack of immune cell-specific methylation data. As more epigenetic data are compiled on both patients and immune cells, these methods may serve as good complementary analyses to be performed alongside expression-based analyses.
Together, these methods can be applied to quickly assess the levels of patient tumor immune infiltration for a large number of cell types. When used in conjunction with immunotherapy response data, these methods can be used to identify the cell types likely involved in response or resistance to any given cancer treatment. As clinical trials on various therapies, including anti-VISTA, continue to generate data, these methods will greatly enhance our ability to provide individualized care to increase clinical responses. 
| Computational approaches to identifying neoantigens
108,109
The variable nature of both somatic mutations and the MHC loci, known as human leukocyte antigen (HLA) in humans, makes the identification of neoantigens highly specific for a given patient.
As such, there have now been several tools developed to aid in the identification of neoantigens from individual tumor DNA sequencing data. These tools typically perform one of three steps necessary in neoantigen identification: somatic mutation identification, 110-116 HLA typing, [117] [118] [119] [120] [121] [122] and neoantigen-MHC binding affinity prediction. 123 In addition, some pipelines have been created such as, pVAC-Seq, to integrate several of these steps together while also accounting for the coverage and expression information that may confound sequencing based studies. 124 As these approaches continue to evolve and neoantigen prediction becomes more routine, our ability to identify biomarkers indicative of immune infiltration and response to immunotherapeutic approaches should be greatly improved.
| Integrating genomic data to predict immunotherapy response
While there are currently no studies that use patient genomic data to predict anti-VISTA immunotherapy response, there have been several studies that use gene expression or DNA sequencing information collected from pretreatment patient cohorts to identify the genomic features associated with response to anti-CTLA-4 and anti-PD-1 therapy.
In a study on CTLA-4 blockade response, whole exome sequencing was performed on 110 pretreatment melanoma tumor biopsies and their matching germline tissue samples. In addition to this, RNAseq data were obtained from 40 of these biopsies, enabling comprehensive genomic analyses to be performed on a small patient cohort. This study found using several of the methods described above that higher mutation and neoantigen counts were associated with clinical benefit to treatment with ipilimumab. Additionally, they found through gene expression analyses that the expression of cytolytic genes, which are indicative of cytotoxic cell infiltration, was also linked to improved ipilimumab response.
125
Similar studies have been performed to examine the genomic correlates of response to anti-PD-1 therapy. One analysis examined the relationship between mutation burden and response to pembrolizumab in non-small cell lung cancer (NSCLC). This group found that higher mutation load was associated with improved progression-free survival, and sensitivity to treatment. 126 In a later study focusing on melanoma, whole exome sequencing was performed on a collection of 38 pretreatment or early on-treatment tumors and of these 38, RNA sequencing information was collected from 27 of them. Interestingly, this study did not find a relationship between mutation load and improved anti-PD-1 response. However, clinical benefit was associated with mutations in the DNA repair gene BRCA2. Additionally, this group showed that genes involved in mesenchymal transition, angiogenesis, and T cell suppression were more highly expressed in the nonresponsive group relative to the responsive group.
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In addition to these studies, a follow-up study was performed to examine the effect of neoantigen intratumor heterogeneity on tumor immune response and found, using the anti-PD-1 NSCLC and anti-CTLA-4 melanoma datasets mentioned above, that clonal neoantigen burden was associated with overall survival and response to CTLA-4
and PD-1 blockade in melanoma and non-small cell lung cancer respectively. 128 This analysis demonstrates the high level of complexity behind the tumor immune response and its role on immunotherapy sensitivity. However, the genomic data obtained from the small patient cohorts included in the study led to significant insights that could not have been obtained through other methods.
Together, these analyses show the potential of using patient genomic data to identify biomarkers for immunotherapy response.
Interestingly, there was a high amount of discordance between each of the studies, demonstrating the need for additional immunotherapy datasets encompassing larger numbers of patients. The differences between genomic correlates associated with anti-PD-1 and anti-CTLA-4 blockade additionally suggests that response to each type of immunotherapy may be dependent on unique molecular mechanisms.
Going forward, similar studies on anti-VISTA could provide a large amount of information regarding the molecular mechanisms involved in anti-VISTA response, as well as predictive biomarkers that could be used to identify patients most likely to be responsive to the drug.
| CONCLUSIONS
Due to the success of targeting the negative checkpoint regulators CTLA-4, PD-1, and PD-L1 to treat cancer, a spotlight has been cast on this entire family of molecules. VISTA has several unique features that suggest that it functions non-redundantly to PD-1. Consequently, therapeutic treatment with antibody targeting it may be beneficial not only as a monotherapy, but also in combination with other treatments.
Further studies are also needed to help identify genetic signatures that can provide further insight into the mechanism of action of therapy and identification of patients most likely to respond to treatment.
